High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance

  1. García-Marco, J.A.
  2. Jiménez, J.L.
  3. Recasens, V.
  4. Zarzoso, M.F.
  5. González-Barca, E.
  6. De Marcos, N.S.
  7. Ramírez, M.J.
  8. Parraga, F.J.P.
  9. Yañez, L.
  10. De La Serna Torroba, J.
  11. Malo, M.D.G.
  12. Ariznavarreta, G.D.
  13. Persona, E.P.
  14. Guinaldo, M.A.R.
  15. De Paz Arias, R.
  16. Llanos, E.B.
  17. Jarque, I.
  18. Del Carmen Fernandez Valle, M.
  19. Tatay, A.C.
  20. De Oteyza, J.P.
  21. Martin, E.M.D.
  22. Fernández, I.P.
  23. Martinez, R.M.
  24. Costa, M.A.A.
  25. Champ, D.
  26. Suarez, J.G.
  27. Díaz, M.G.
  28. Ferrer, S.
  29. Carbonell, F.
  30. García-Vela, J.A.
  31. Erakutsi egile guztiak +
Aldizkaria:
Haematologica

ISSN: 1592-8721,  0390-6078

Argitalpen urtea: 2019

Alea: 104

Zenbakia: 11

Orrialdeak: 2249-2257

Mota: Artikulua

DOI: 10.3324/HAEMATOL.2018.204891 GOOGLE SCHOLAR lock_openSarbide irekia editor

Garapen Iraunkorreko Helburuak

Datuen iturria: Scopus